[Epidemiologic study of sudden death in adults from 15 to 74 years of age in the city of São Paulo].

R. Laurenti,J. M. de Souza,M. Prado,S. Gotlieb

1980-07-01

Arquivos Brasileiros de Cardiologia

Abstract:

What problem does this paper attempt to address?

Data from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Jhanelle E. Gray,Andreas Saltos,Tawee Tanvetyanon,Eric B. Haura,Ben Creelan,Scott J. Antonia,Michael Shafique,Hong Zheng,Wenjie Dai,James J. Saller,Zhihua Chen,Nishan Tchekmedyian,Kristen Goas,Ram Thapa,Theresa A. Boyle,Dung-Tsa Chen,Amer A. Beg

DOI: https://doi.org/10.1158/1078-0432.ccr-19-1305

IF: 13.801

2019-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: Histone deacetylase inhibitors (HDACi) enhance tumor immunogenicity through several mechanisms and may improve response to immune checkpoint inhibitors (ICIs). In a phase I/Ib trial, we tested the oral HDACi vorinostat combined with the programmed cell death protein 1 inhibitor pembrolizumab in advanced/metastatic non–small cell lung cancer. Patients and Methods: Patients received intravenous pembrolizumab (200 mg every 3 weeks) plus oral vorinostat (200 or 400 mg/day). Primary endpoint was safety/tolerability. Secondary endpoints included response rate, progression-free survival, disease control rate (DCR), and overall survival. Tumor gene expression changes, T-cell density, and myeloid cell levels were studied in serial tissue specimens. Results: Thirty-three patients were treated (13 in phase I, 20 in phase Ib). In phase I, both ICI-naïve and ICI-pretreated patients were enrolled to determine dose-limiting toxicities (DLT). No DLTs were observed, and the recommended phase I dose was pembrolizumab 200 mg and vorinostat 400 mg. Any-grade adverse events were mainly fatigue (33%) and nausea/vomiting (27%). Of six ICI-naïve and 24 ICI-pretreated patients evaluable for response, four (13%) had partial response [two confirmed, one unconfirmed with subsequent prolonged stable disease (SD), one unconfirmed with subsequent progressive disease (PD)], 16 (53%) had SD, and 10 (33%) had PD for a DCR of 67%. In the ICI-pretreated cohort, three patients (one confirmed, two unconfirmed) had partial response and 10 had SD. Pretreatment CD8+ T-cell presence in tumor stromal regions was associated with treatment benefit. Conclusions: Pembrolizumab plus vorinostat was well tolerated and demonstrated preliminary antitumor activity despite progression on prior ICI treatment.
Neoadjuvant Hypofractionated Radiotherapy Combined with Pembrolizumab Plus Chemotherapy for Potentially Resectable Non-Small Cell Lung Cancer: A Phase Ib Study.

Naixin Ding,Lijun Zhao,Shuai Zhang,Ninglei Qiu,Xue Song,Cheng Kong,Ning Jiang,Yang Zhao,Jianfeng Huang,Feng Jiang,Ming Jiang,Zihao Zhu,Rong Yin,Binhui Ren,Xiangzhi Zhu,Ming Li

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.8054

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:8054 Background: Neoadjuvant PD-1 inhibitor plus chemotherapy in resectable non-small cell lung cancer (NSCLC) has become a standard of care. hypofractioned radiotherapy (HFRT) served as an immunomodulator and enhanced the effect of preoperative immunotherapy. In this phase Ib study, we evaluated the safety and feasibility of neoadjuvant HFRT with pembrolizumab plus chemotherapy in patients with potentially resectable stage III NSCLC. Methods: Patients with potentially resectable stage III NSCLC with EGFR/ALK wild-type were recruited to receive HFRT to the primary tumor followed by two cycles of pembrolizumab (100 mg/body) plus platinum-based doublet chemotherapy (Q3W). HFRT was delivered using 3 daily fractions, with a dose of 24 Gy for peripheral lesions and 12 Gy for central lesions. Central lesion is defined as a 2 cm area around the pulmonary artery and main bronchus. The decision for surgery was made through multidisciplinary team (MDT) discussion within a 4–6-week period after the completion of neoadjuvant treatment. Patients underwent surgery followed by adjuvant pembrolizumab for 2 years. Primary endpoint was safety. Secondary endpoints were efficacy, such as pathological complete response (pCR), progression-free survival (PFS), and overall survival (OS). Results: Between April 2021 and November 2023, 17 patients were enrolled with a median age of 66 years (range 54-74) and 15 (88.2%) having squamous cell lung cancer. 12 (70.6%) patients had stage IIIB disease, and 10 (58.8%) had central primary lesion. PD-L1 was ≥1% in 9 patients (52.9%). All patients received HFRT and at least one cycle of immunochemotherapy. No grade 3 or high adverse events were observed during neoadjuvant therapy. Only one patient had grade 1 nephrotoxicity, and another patient had grade 2 pneumonitis. A partial response was achieved in 16 out of 17 patients (94.1%), while one patient had stable disease after neoadjuvant therapy. Following MDT discussion, 11 patients (64.7%) met the surgical standards, while the remaining 6 patients were transitioned to definitive chemoradiotherapy. Among the 11 patients who underwent surgery, 8 (72.7%) achieved R0 resection, and 6 patients (54.5%) attained pCR. Only one patient died from intraoperative bleeding, and the remaining patients were followed up. The median PFS was 21.7 months, median OS were not reached, and the 2-year OS rate was 85.6%. The study was terminated early due to slow recruitment. Conclusions: Neoadjuvant HFRT with immunotherapy for potentially resectable stage III NSCLC is a tolerable treatment with an improved surgical conversion rate and pCR rate. Clinical trial information: ChiCTR2100045361.
A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer

Alice Y Ho,Christopher A Barker,Brittany B Arnold,Simon N Powell,Zishuo I Hu,Ayca Gucalp,Lizza Lebron-Zapata,Hannah Y Wen,Cindy Kallman,Alessandro D'Agnolo,Zhigang Zhang,Jessica Flynn,Samantha A Dunn,Heather L McArthur

DOI: https://doi.org/10.1002/cncr.32599

IF: 6.9209

2020-02-15

Cancer

Abstract:Background: The current study was conducted to evaluate the efficacy and safety of pembrolizumab-mediated programmed cell death protein 1 inhibition plus radiotherapy (RT) in patients with metastatic triple-negative breast cancer who were unselected for programmed death-ligand 1 expression. Methods: The current study was a single-arm, Simon 2-stage, phase 2 clinical trial that enrolled a total of 17 patients with a median age of 52 years (range, 37-73 years). An RT dose of 3000 centigrays (cGy) was delivered in 5 daily fractions. Pembrolizumab was administered intravenously at a dose of 200 mg within 3 days of the first RT fraction, and then every 3 weeks ± 3 days until disease progression. The median follow-up was 34.5 weeks (range, 2.1-108.3 weeks). The primary endpoint of the current study was the overall response rate (ORR) at week 13 in patients with unirradiated lesions measured using Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Secondary endpoints included safety and progression-free survival. Exploratory objectives were to identify biomarkers predictive of ORR and progression-free survival. Results: The ORR for the entire cohort was 17.6% (3 of 17 patients; 95% CI, 4.7%-44.2%), with 3 complete responses (CRs), 1 case of stable disease, and 13 cases of progressive disease. Eight patients died prior to week 13 due to disease progression. Among the 9 women assessed using RECIST version 1.1 at week 13, 3 (33%) achieved a CR, with a 100% reduction in tumor volume outside of the irradiated portal. The CRs were durable for 18 weeks, 20 weeks, and 108 weeks, respectively. The most common grade 1 to 2 toxicity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0) was dermatitis (29%). Four grade 3 adverse events were attributed to pembrolizumab: fatigue, lymphopenia, and infection. No were no grade 4 adverse events or treatment-related deaths reported. Conclusions: The combination of pembrolizumab and RT was found to be safe and demonstrated encouraging activity in patients with poor-prognosis, metastatic, triple-negative breast cancer who were unselected for programmed death-ligand 1 expression. Larger clinical trials of checkpoint blockade plus RT with predictive biomarkers of response are needed.
A Phase 2 Clinical Trial of Pembrolizumab with Radiation Following Progression on anti-PD-1 Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

J.D. Schoenfeld,Y.H. Chen,L. Gunasti,A. Droznin,J. Baginska,A. Nau,J. Weirather,I. Gomez Diaz,D.N. Margalit,R.B. Tishler,K.J. Fitzgerald,R.H. Mak,R. Uppaluri,K. Sehgal,G.J. Hanna,R.I. Haddad,J. So

DOI: https://doi.org/10.1016/j.ijrobp.2024.01.075

IF: 8.013

2024-04-01

International Journal of Radiation Oncology*Biology*Physics

Abstract:Purpose/Objective(s) Treatment options for patients (pts) with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who have progressed on anti-PD-1 directed therapy are limited. Some of these pts may have more limited disease (oligo) progression that may be amenable to radiation therapy (RT). RT has not been tested prospectively in this setting. Materials/Methods We performed a Phase 2 trial investigating focused RT with concurrent pembrolizumab (pembro) in pts with SCCHN whose disease progressed on prior PD-1 blockade. Cohort A allowed RT to a single lesion while Cohort B allowed for RT to up to 6 lesions. The primary endpoint was overall progression-free survival (PFS) at 3 months. A two-stage design was used in each cohort with the goal to distinguish 3-month (mo) PFS >65% vs. 35%. Cytometry by time of flight (CyTOF) evaluated circulating immune populations in peripheral blood samples obtained at baseline and over the course of therapy. Results Eighteen pts were enrolled, 6 in Cohort A and 12 in Cohort B. Eight (44%) pts had HPV+ disease (3 in Cohort A, 5 in Cohort B); 16 received prior chemoRT to the HN. Median number of metastases were 8.5 (Cohort A, range 1,>10) and 2 (Cohort B, range 1,>10). The most common protocol RT dose was 40 Gy in 5 fractions (n=9). The two most common sites of radiation were head and neck (n=10) and lung (n=10). Treatment was generally well tolerated with 2 pts experiencing grade 3 toxicity (fatigue, esophagitis) and 2 pts grade 4 toxicity (laryngeal edema, bleeding), all in Cohort B. Median PFS for Cohort A was 1.8 mo (95% CI 0.7-32.9 mo) with one pt progression-free at 3 mo (17%); therefore, this cohort did not proceed to the second stage. In Cohort B, median PFS was 6.5 mo (95% CI 3.3-10.2) with 8/12 pts progression free at 3mo (67%). PFS was associated with smaller RT target (prescription isodose <80cm3, p=0.04), 1-2 vs. >2 metastases (p=0.01), and RT to >50% of metastases (p<0.0001). Median OS was 7.6 mos (95% CI 0.7-32.9 mo) in Cohort A and 10.2 mos in Cohort B (95% CI 6.0-49.7 mo). CyTOF identified that the fraction of circulating CD8+ central memory T-cells (Tcm) was higher at baseline (mean freq. 3.0% vs. 0.9%) and remained elevated following cycle 2 of pembro (mean freq. 3.2% vs. 0.6%), in pts progression free >3mo. Expression of the trafficking and homing marker CXCR5 was also elevated on treatment (p adj.= 0.03) in memory B-cells from pts with PFS>3 mo. Conclusion This prospective phase 2 trial evaluated RT in R/M SCCHN pts following disease oligo-progression on prior anti-PD-1 therapy. RT/pembro resulted in more promising outcomes when RT was used to target the majority/entirety of measurable disease, with median PFS exceeding 6mo. Multiplexed immune cell measurements identified potential biomarkers that may help select patients who may benefit from integrated RT following progression on anti-PD-1 therapy.

oncology,radiology, nuclear medicine & medical imaging
[Results of tests with clomiphene and choriogonadotropin in men with oligozoospermia treated with longterm antiestrogens].

M. Mędraś,L. Terpiłowski,D. Kiełkiewicz,J. Winowski,G. Ziotas

1996-02-01

Abstract:The evaluation was made of the response to testosterone and oestradiol in the test (50 mg twice daily for 10 days) and HCG test (6000 units of Biogonadyl through 2 days) performed on 21 normospermic (fertile) males and on patients with normogonadotropic, idiopathic oligozoospermia, positively (12 patients) or negatively (24 males) reacting to the longterm Clostilbegyt treatment (50 mg daily for 240 days). It was shown that patients with oligozoospermia who do not react with an increase of spermatozoa during the longterm antioestrogen treatment had higher response of oestradiol in the dynamic test (+ 118.9%) than the normospermic males (+ 60.8%) or the oligozoospermic who showed positive semenologic response to the treatment (+ 58.8%). The similar reaction of oestradiol was shown in the HCG stimulation. In the hiperoestrogenism phenomenon the authors noticed the cause of lack of positive semenologic effects of the longterm antioestrogen treatment.
Delayed primary closure of Korean war wounds.

D. Fisher

1953-06-01

Abstract:
A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC

Jyoti Malhotra,Yong Lin,Malini Patel,Michael J Yellin,Emmanuel Zachariah,Curtis Krier,Ankit Saxena,Salma K Jabbour

DOI: https://doi.org/10.1016/j.jtocrr.2024.100687

2024-05-16

Abstract:Introduction: Anti-programmed cell death 1 (PD-1) immunotherapy is the standard of care for metastatic NSCLC but many tumors develop resistance. We hypothesized that combining a T-cell agonist such as varlilumab (anti-CD27 antibody) with checkpoint inhibition may be synergistic and this synergy may be potentiated further by using targeted radiation (RT). Methods: We conducted an open-label, single-center, phase I trial (NCT04081688) to determine the safety and clinical benefit of the atezolizumab and varlilumab in combination with palliative RT in patients with advanced or metastatic NSCLC with progression on prior programmed cell death ligand 1therapy. On day 1 of each 21-day cycle, patients received varlilumab followed by atezolizumab on day 2. RT to a lung lesion was administered between cycle 1 and cycle 2. Results: A total of 15 patients were enrolled (one patient did not start treatment). The median age was 64 years; 10 patients were female. Eight patients (57%) had at least one treatment-related adverse event (AE) and 7 (50%) had at least one grade III or worse treatment-related AE. There was only one grade III immune-related AE requiring steroids (1 diarrhea and colitis); there were no treatment-related deaths. Of the 12 patients evaluable for efficacy, three patients had stable disease (2 with stable disease > 4 mo) and the clinical benefit rate was 25%. The median progression-free survival was two months and the median overall survival was 6.4 months. Conclusions: Varlilumab in combination with atezolizumab and RT was safe and well tolerated; no additional signal was identified for toxicity. Clinical activity for the combination was modest with 25% of patients with stable disease as the best response.
Abstract CT120: Phase II study of radiotherapy in combination with chemotherapy and immunotherapy in patients with PD-L1-positive metastatic triple-negative breast cancer

Anna R. Schreiber,Jodi Kagihara,Andrew Nicklawsky,Dexiang Gao,Anosheh Afghahi,Anthony Elias,Peter Kabos,Elena Shagisultanova,Todd Pitts,Julie Lang,Sana Karam,Virginia Borges,Christine Fisher,Jennifer R. Diamond

DOI: https://doi.org/10.1158/1538-7445.am2022-ct120

IF: 11.2

2022-06-17

Cancer Research

Abstract:Background: Metastatic triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking hormone receptor expression and HER2 over-expression. Metastatic TNBC has been difficult to treat due to a general lack of targeted therapies, however, immunotherapy has shown substantial activity in a subset of patients. In metastatic TNBC patients with PD-L1-positive (combined positive score (CPS) ≥ 10) disease, KEYNOTE-355 demonstrated that addition of pembrolizumab (PD-1 inhibitor) to chemotherapy (nab-paclitaxel, paclitaxel, or carboplatin/gemcitabine) prolonged median progression free survival (PFS) compared to chemotherapy alone (9.7 months vs 5.6 months). Median 1-year PFS was also increased from 12.0% to 39.1% in these patients treated with pembrolizumab. These data led to the FDA approval of pembrolizumab with chemotherapy in PD-L1-positive metastatic TNBC patients. Despite these encouraging results, the majority of patients do not have long-term disease control. Radiotherapy (RT) in combination with immunotherapy and chemotherapy represents a promising avenue to prolong long-term response. RT can stimulate cellular damage and cause the release of tumor antigens, promoting a local T cell response. In addition, localized RT can result in the shrinkage of distant sites of metastasis via the abscopal effect when used with immunotherapy. The purpose of this study is to investigate the benefit of combining RT with pembrolizumab and chemotherapy in patients with metastatic PD-L1-positive TNBC. Methods: This two-stage, single-arm phase II study will assess the efficacy of RT in combination with nab-paclitaxel/paclitaxel plus pembrolizumab in PD-L1-positive unresectable or metastatic TNBC patients aged ≥18 years. To be included, patients must have only received < 1 prior line of systemic therapy in the metastatic setting or adjuvant/neoadjuvant setting if metastatic recurrence was within 12 months of treatment. The primary endpoint of the study is the 1-year PFS rate and a total of 29 subjects will be enrolled. Patients will be treated first with RT followed by the initiation of systemic therapy within seven days. Ablative RT will be directed at 1-4 sites of metastatic disease in 3 fractions of 8 Gy each. Nab-paclitaxel or paclitaxel will be given weekly day 1, day 8 every 3 weeks and pembrolizumab will be given every 3 weeks. Imaging will be repeated every 9 weeks to assess response based on RECIST 1.1. Systemic treatment will be continued until disease progression or intolerable toxicity. Treatment beyond progression will be allowed in certain patients who had initial response followed by progression. In these patients, repeat RT to new sites of disease can be administered with continuation of pembrolizumab to investigate the potential of re-sensitizing patients to immunotherapy. Blood will be collected before and after treatment for immune profiling. The sample size was determined using a null hypothesis for the 1-year PFS rate of 39% and an alternate hypothesis of 60%. The sample size of 29 yields a power of 80% to detect this difference with an alpha of 0.1 (1-sided). An interim analysis will be performed after enrollment of seventeen subjects in stage one. Citation Format: Anna R. Schreiber, Jodi Kagihara, Andrew Nicklawsky, Dexiang Gao, Anosheh Afghahi, Anthony Elias, Peter Kabos, Elena Shagisultanova, Todd Pitts, Julie Lang, Sana Karam, Virginia Borges, Christine Fisher, Jennifer R. Diamond. Phase II study of radiotherapy in combination with chemotherapy and immunotherapy in patients with PD-L1-positive metastatic triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr CT120.

oncology
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA

Mohammad K Khan,Tahseen H Nasti,Joshua Y Qian,Troy J Kleber,Jeffrey M Switchenko,Jonathan L Kaufman,Ajay J Nooka,Madhav V Dhodapkar,Zachary S Buchwald,Daby Obiekwe,Sagar Lonial,Rafi Ahmed

DOI: https://doi.org/10.1016/s2352-3026(24)00105-4

IF: 30.153

2024-05-26

The Lancet Haematology

Abstract:Summary Background Currently, the use of radiotherapy alone for people with multiple myeloma is limited to palliation of pain, pending fracture, and control of spinal-cord compression. Single immune-checkpoint inhibitors, such as anti-programmed death-1 (anti-PD1), have not been successful. We aimed to evaluate the activity and safety of the combination of pembrolizumab and low-dose, single-fraction, hypofractionated radiotherapy to treat patients with relapsed or refractory multiple myeloma. Methods For this prospective, single-centre, single-group, open-label, phase 2 trial, we recruited patients with relapsed or refractory multiple myeloma from the Winship Cancer Institute (Emory University, Atlanta, GA, USA). Key inclusion criteria were aged 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, relapsed or refractory multiple myeloma as indicated by progression under International Myeloma Working Group (IMWG) criteria, and adequate candidacy for both pembrolizumab and radiotherapy. Baseline and post-treatment assessments were serial bone-marrow biopsy, peripheral blood collections, staging, serial serum and urine paraprotein analysis, serial PET–CT imaging, and a physical examination. On day 1, patients received hypofractionated 8 gray in 1 fraction (8 Gy/1 fx) radiotherapy to either symptomatic or progressing extra-osseous or osseous myeloma sites. Patients also received pembrolizumab (200 mg/kg intravenously) on day 2 or 3, then once every 3 weeks (±7 days) for 2 years or until progressive disease, unacceptable toxicity, withdrawal of consent, loss to follow-up, or death. Dose reduction and interruptions were not allowed. The primary outcome was acute toxicity defined as grade 3 or worse toxicity at 3 months within the radiated site when used in combination with pembrolizumab. All patients were analysed per protocol and included in safety analyses. This trial is registered on ClinicalTrials.gov ( NCT03267888 ); it is completed and closed to accrual. Findings 32 patients were screened between June 1, 2018, and Sept 2, 2022, and 25 were enrolled in the trial and treated on protocol. Of the 25 treated patients, 11 (44%) were female and 14 (56%) were male. 19 (76%) patients were White and six (24%) were Black or African American. Toxicity, as the primary outcome, was deemed to be acceptable as no grade 4 or 5 adverse events were observed. At 3-month follow-up, eight (32%) of 25 patients had treatment benefit (one had stable disease, three had partial response, two had very good partial response, and two had complete response). There was no grade 3 or worse radiation-related toxicity within irradiated volumes. One (4%) patient of the 25 who received combination treatment had a grade 3 pembrolizumab-related adverse event. There were no treatment-related deaths. Interpretation Combination treatment of low-dose, single-fraction radiotherapy with pembrolizumab was safe, with early promise of response activity. Our approach could be an option for patients with relapsed or refractory multiple myeloma who have not responded to previous treatment. Larger trials to substantiate our findings are needed. Funding Merck Sharp & Dohme.

hematology
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

Nikhil Yegya-Raman,Abigail T Berman,Christine A Ciunci,Cole Friedes,Eva Berlin,Michelle Iocolano,Xingmei Wang,Ching Lai,William P Levin,Keith A Cengel,Shannon E O'Reilly,Roger B Cohen,Charu Aggarwal,Melina E Marmarelis,Aditi P Singh,Lova Sun,Jeffrey D Bradley,John P Plastaras,Charles B Simone 2nd,Corey J Langer,Steven J Feigenberg

DOI: https://doi.org/10.1016/j.ijrobp.2023.08.047

2024-05-01

Abstract:Purpose: Reirradiation (reRT) with proton beam therapy (PBT) may offer a chance of cure while minimizing toxicity for patients with isolated intrathoracic recurrences of non-small cell lung cancer (NSCLC). However, distant failure remains common, necessitating strategies to integrate more effective systemic therapy. Methods and materials: This was a phase 2, single-arm trial (NCT03087760) of consolidation pembrolizumab after PBT reRT for locoregional recurrences of NSCLC. Four to 12 weeks after completion of 60 to 70 Gy PBT reRT, patients without progressive disease received pembrolizumab for up to 12 months. Primary endpoint was progression-free survival (PFS), measured from the start of reRT. Secondary endpoints were overall survival (OS) and National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 toxicity. Results: Between 2017 and 2021, 22 patients received PBT reRT. Median interval from prior radiation end to reRT start was 20 months. Most recurrences (91%) were centrally located. Most patients received concurrent chemotherapy (95%) and pencil beam scanning PBT (77%), and 36% had received prior durvalumab. Fifteen patients (68%) initiated consolidation pembrolizumab on trial and received a median of 3 cycles (range, 2-17). Pembrolizumab was discontinued most commonly due to toxicity (n = 5; 2 were pembrolizumab-related), disease progression (n = 4), and completion of 1 year (n = 3). Median follow-up was 38.7 months. Median PFS and OS were 8.8 months (95% CI, 4.2-23.7) and 22.8 months (95% CI, 6.9-not reached), respectively. There was only one isolated in-field failure after reRT. Grade ≥3 toxicities occurred in 10 patients (45%); 2 were pembrolizumab-related. There were 2 grade 5 toxicities, an aorto-esophageal fistula at 6.9 months and hemoptysis at 46.8 months, both probably from reRT. The trial closed early due to widespread adoption of immunotherapy off-protocol. Conclusions: In the first-ever prospective trial combining PBT reRT with consolidation immunotherapy, PFS was acceptable and OS favorable. Late grade 5 toxicity occurred in 2 of 22 patients. This approach may be considered in selected patients with isolated thoracic recurrences of NSCLC.
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

Nora Sundahl,Katrien De Wolf,Sylvie Rottey,Karel Decaestecker,Daan De Maeseneer,Annabel Meireson,Els Goetghebeur,Valérie Fonteyne,Sofie Verbeke,Pieter De Visschere,Dries Reynders,Mireille Van Gele,Lieve Brochez,Piet Ost

DOI: https://doi.org/10.1186/s12967-017-1251-3

2017-06-29

Abstract:Background: Current first-line standard of therapy for metastatic urothelial carcinoma is platinum-based combination chemotherapy. Pembrolizumab in phase III has demonstrated a promising overall response rate of 21.1% in patients with progression or recurrence after platinum-based chemotherapy. Preclinical and clinical evidence suggests that radiotherapy has a systemic anti-cancer immune effect and can increase the level of PD-L1 and tumor infiltrating lymphocytes in the tumor microenvironment. These findings gave rise to the hypothesis that the combination of radiotherapy with anti-PD1 treatment could lead to a synergistic effect, hereby enhancing response rates. Methods: The phase I part will assess the dose limiting toxicity of the combination treatment of stereotactic body radiotherapy (SBRT) with four cycles of pembrolizumab (200 mg intravenously, every 3 weeks) in patients with metastatic urothelial carcinoma. The dose of both pembrolizumab and SBRT will be fixed, yet the patients will be randomized to receive SBRT either before the first cycle of pembrolizumab or before the third cycle of pembrolizumab. SBRT will be delivered (24 Gy in 3 fractions every other day) to the largest metastatic lesion. Secondary objectives include response rate according to RECIST v1.1 and immune related response criteria, progression-free survival and overall survival. The systemic immune effect triggered by the combination therapy will be monitored on various time points during the trial. The PD-L1/TIL status of the tumors will be analyzed via immunohistochemistry and response rates in the subgroups will be analyzed separately. A Simon's two-stage optimum design is used to select the treatment arm associated with the best response rate and with acceptable toxicity to proceed to the phase II trial. In this phase, 13 additional patients will be accrued to receive study treatment. Discussion: The progress made in the field of immunotherapy has lead to promising breakthroughs in various solid malignancies. Unfortunately, the majority of patients do not respond. The current trial will shed light on the toxicity and potential anti-tumor activity of the combination of radiotherapy with anti-PD1 treatment and may identify potential new markers for response and resistance to therapy. Trial registration this trial is registered on clinicaltrials.gov (NCT02826564).
A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes

Amit Maity,Rosemarie Mick,Ramesh Rengan,Tara C Mitchell,Ravi K Amaravadi,Lynn M Schuchter,Daniel A Pryma,Dana M Patsch,Alisha P Maity,Andy J Minn,Robert H Vonderheide,John N Lukens

DOI: https://doi.org/10.1080/2162402X.2020.1863631

2021-01-31

OncoImmunology

Abstract:We conducted a phase I dose-escalation trial of radiation with ipilimumab in patients with melanoma with ≥2 metastatic lesions. Here, we report the final full clinical analysis. Patients received RT (6 or 8 Gy x 2 or 3 doses) to a single lesion followed by 4 cycles of ipilimumab. The primary endpoint was maximum tolerated dose of RT, and secondary endpoint was response at non-radiated sites. Twenty-two patients with treatment-naïve (n = 11) or treatment-refractory (n = 11) Stage IV melanoma were enrolled. There were 31 treatment-related adverse events (AEs), of which 16 were deemed immune-related. Eleven patients had grade 3 AEs (no grade 4/5). There were no dose-limiting toxicities related to the radiation/ipilimumab combination. Five of 22 patients (22.7%, 95% CI 7.8-45.4%) had partial response as best response and three (13.6%) had stable disease. Median overall survival was 10.7 months (95% CI, 4.9 months to not-estimable) and median progression-free survival 3.6 months (95% CI, 2.9 months to 7.8 months). Seven patients were still alive at the time of last follow-up (median follow-up 89.2 months), most of whom received pembrolizumab after progression. Radiotherapy followed by ipilimumab was well tolerated and yielded a response rate that compares favorably to the objective response rate with ipilimumab alone. Furthermore, 32% of patients are long-term survivors, most of whom received pembrolizumab. Based on these results, the recommended dose that was used in subsequent Phase 2 trials was 8 Gy x 3 doses. Clinical Trial Registration: NCT01497808 (www.clinicaltrials.gov).
Phase 2 Study of Pembrolizumab in Patients with Advanced Rare Cancers.

Aung Naing,Funda Meric-Bernstam,Bettzy Stephen,Daniel D. Karp,Joud Hajjar,Jordi Rodon Ahnert,Sarina A. Piha-Paul,Rivka R. Colen,Camilo Jimenez,Kanwal P. Raghav,Renata Ferrarotto,Shi-Ming Tu,Matthew Campbell,Linghua Wang,Sarjeel H. Sabir,Coya Tapia,Chantale Bernatchez,Michael Frumovitz,Nizar Tannir,Vinod Ravi,Saria Khan,Jeane M. Painter,Abulrahman Abonofal,Jing Gong,Anas Alshawa,Lacey M. McQuinn,Mingxuan Xu,Sara Ahmed,Vivek Subbiah,David S. Hong,Shubham Pant,Timothy A. Yap,Apostolia M. Tsimberidou,Ecaterina E. Ileana Dumbrava,Filip Janku,Siqing Fu,Richard M. Simon,Kenneth R. Hess,Gauri R. Varadhachary,Mouhammed Amir Habra

DOI: https://doi.org/10.1136/jitc-2019-000347

IF: 12.469

2020-01-01

Journal for ImmunoTherapy of Cancer

Abstract:BackgroundPatients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients with advanced rare cancers.MethodsIn this open-label, phase 2 trial, patients with advanced rare cancers whose tumors had progressed on standard therapies, if available, within the previous 6 months were enrolled in nine tumor-specific cohorts and a 10th cohort for other rare histologies. Pembrolizumab 200 mg was administered intravenously every 21 days. The primary endpoint was non-progression rate (NPR) at 27 weeks; secondary endpoints were safety and tolerability, objective response rate (ORR), and clinical benefit rate (CBR).ResultsA total of 127 patients treated between August 15, 2016 and July 27, 2018 were included in this analysis. At the time of data cut-off, the NPR at 27 weeks was 28% (95% CI, 19% to 37%). A confirmed objective response (OR) was seen in 15 of 110 (14%) evaluable patients (complete response in one and partial response in 14). CBR, defined as the percentage of patients with an OR or stable disease ≥4 months, was 38% (n=42). Treatment was ongoing in 11 of 15 patients with OR at last follow-up. In the cohort with squamous cell carcinoma (SCC) of the skin, the NPR at 27 weeks was 36%, ORR 31%, and CBR 38%. In patients with adrenocortical carcinoma (ACC), NPR at 27 weeks was 31%, ORR 15%, and CBR 54%. In the patients with carcinoma of unknown primary (CUP), NPR at 27 weeks was 33%, ORR 23%, and CBR 54%. In the paraganglioma–pheochromocytoma cohort, NPR at 27 weeks was 43%, ORR 0%, and CBR 75%. Treatment-related adverse events (TRAEs) occurred in 66 of 127 (52%) patients, and 12 (9%) had grade ≥3 TRAEs. The most common TRAEs were fatigue (n=25) and rash (n=17). There were six deaths, all of which were unrelated to the study drug.ConclusionsThe favorable toxicity profile and antitumor activity seen in patients with SCC of skin, ACC, CUP, and paraganglioma–pheochromocytoma supports further evaluation of pembrolizumab in this patient population.Trial registration numberNCT02721732
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Greg A. Durm,Salma K. Jabbour,Sandra K. Althouse,Ziyue Liu,Ahad A. Sadiq,Robin T. Zon,Shadia I. Jalal,Goetz H. Kloecker,Michael J. Williamson,Karen L. Reckamp,Robert M. Langdon,Ebenezer A. Kio,Ryan D. Gentzler,Bamidele A. Adesunloye,Wael A. Harb,Radhika V. Walling,Michael L. Titzer,Nasser H. Hanna

DOI: https://doi.org/10.1002/cncr.33083

IF: 6.9209

2020-07-22

Cancer

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Five‐year overall survival (OS) for patients with unresectable stage III non–small cell lung cancer (NSCLC) is poor. Until recently, a standard of care was concurrent chemoradiation alone. Patients with metastatic NSCLC treated with anti–programmed death 1 antibodies have demonstrated improved OS. This trial evaluated pembrolizumab as consolidation therapy after concurrent chemoradiation in patients with unresectable stage III disease.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Patients with unresectable stage III NSCLC received concurrent chemoradiation with cisplatin and etoposide, cisplatin and pemetrexed, or carboplatin and paclitaxel and 59.4 to 66.6 Gy of radiation. Patients with nonprogression of disease were enrolled and received pembrolizumab (200 mg intravenously every 3 weeks for up to 12 months). The primary endpoint was the time to metastatic disease or death (TMDD). Secondary endpoints included progression‐free survival (PFS) and OS.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The median follow‐up for 93 patients (92 for efficacy) was 32.2 months (range, 1.2‐46.6 months). The median TMDD was 30.7 months (95% confidence interval [CI], 18.7 months to not reached), which was significantly longer than the historical control of 12 months (<i>P </i> < .0001). The median PFS was 18.7 months (95% CI, 12.4‐33.8 months), and the median OS was 35.8 months (95% CI, 24.2 months to not reached). The 1‐, 2‐, and 3‐year OS estimates were 81.2%, 62.0%, and 48.5%, respectively. Forty patients (43.5%) completed 12 months of treatment (median number of cycles, 13.5). Symptomatic pneumonitis (grade 2 or higher) was noted in 16 patients (17.2%); these cases included 4 grade 3 events (4.3%), 1 grade 4 event (1.1%), and 1 grade 5 event (1.1%). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Consolidation pembrolizumab after concurrent chemoradiation improves TMDD, PFS, and OS in comparison with historical controls of chemoradiation alone. Rates of grade 3 to 5 pneumonitis were similar to those reported with chemoradiation alone.</p></section>

oncology
Ku band second harmonic N-coupled push-push oscillator array using microstrip resonator

K. Kawasaki,Takayuki Tanaka,M. Aikawa

DOI: https://doi.org/10.1109/MWSYM.2010.5518317

2010-05-23

Abstract:This paper presents the second harmonic push-push oscillator array. By using the push-push oscillator, a high frequency signal is easily generated with inexpensive low frequency devices. These push-push oscillators are connected with coupling circuits which are composed of microstrip resonators. The coupling circuit has two ports to connect the push-push oscillators. The reflection constant, S11 and S22, of the coupling circuit are controlled by a varactor diode. In the coupling circuit, the phase of S11 is almost constant, and the other S22 is changed by the reactance of the varactor diode. Therefore, the output signals of the push-push oscillators are generated with different phase. The second harmonic push-push oscillator array is designed and fabricated in Ku band. The basic performance of the oscillator array using two push-push oscillators is basically investigated. The phase shift introduced between two oscillators is 451 degrees at 14.75 GHz. The output power of the second harmonic signal is +0.67 dBm with the phase noise of −107.5 dBc/Hz at the offset frequency of 1 MHz.
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker Correlatives

R.L. Ferris,P. Torres-Saavedra,R. Uppaluri,M. Yao,J. Chen,R. Jordan,J.L. Geiger,S. Jujjavarapu,A. Chakravati,M. Phan,F. Siddiqui,A. Kulkarni,P. Upadhyay,F. Tu,L. Vujanovic,B. Isett,G.L. Sica,J. Harris,Q.T. Le,J. Bauman

DOI: https://doi.org/10.1016/j.ijrobp.2024.01.030

IF: 8.013

2024-04-01

International Journal of Radiation Oncology*Biology*Physics

Abstract:Purpose/Objective(s) Patients with locoregional, pathologically high-risk HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). Targeting PD1 may reverse immunosuppression induced by HNSCC and CRT. Materials/Methods We conducted a phase I trial (n=34) adding pembrolizumab (200mg q3 weeks) to adjuvant CRT, with correlative studies to identify biomarkers of clinical benefit. Eligible patients had resected HPV-negative, AJCC 7 stage III-IV oral cavity, pharynx, or larynx HNSCC, with extracapsular nodal extension or positive margin. We assessed PD-L1 expression using the 22c3 Ab in a CLIA laboratory test and correlated with disease-free survival (DFS) and overall survival (OS) using a combined positive score (CPS) threshold of ≥20/ or <20. The CPS threshold of 1+/< 1 could not be evaluated due to insufficient patients in the <1 group. DFS and OS rates were estimated by Kaplan-Meier method, and groups were compared by 2-sided log-rank tests. Hazard ratios (HR; CPS ≥20/ or <20) were estimated by Cox models. To determine mechanisms and biomarkers of clinical benefit, additional exploratory analyses to assess the relationship between clinical outcomes and serum (Luminex, soluble checkpoints, cytokines, and chemokines), tumor/tissue (single-plex IHC, 7-color multispectral tumor staining, whole-exome sequencing, CD8 T cell infiltration, CD8/Treg ratio, and mutational status), and PBMC (spectral flow cytometry and T cell frequencies and activation states) biomarkers are being performed. Results Adding pembrolizumab to adjuvant CRT was well tolerated. Nine (26.5%) and 25 (73.5%) patients had CPS <20 or ≥20. At a median follow-up of 3.1 years (0.04-3.3), 15 (10) DFS (OS) events were reported, 3 (2) in the CPS <20 group and 12 (8) in the CPS 20+ group. Biomarker effect HR was 1.94 (95% confidence interval [CI] 0.54-6.89; p=0.30) for DFS and 1.70 (95% CI 0.36-8.00; p=0.50) for OS. Two-year DFS estimates were 77.8% (95% CI 50.6-100) for CPS <20 and 52.3% (95% CI 31.9-72.7) for CPS 20+. Two-year OS estimates were 77.8% (95% CI 50.6-100) for CPS <20 and 69.6% (95% CI 50.8-88.4) for CPS 20+. Conclusion In this small patient sample, no significant association of PD-L1 expression with clinical outcomes was identified. Circulating inflammatory cytokine and immune checkpoint biomarkers have been performed and are being correlated with clinical outcomes.

oncology,radiology, nuclear medicine & medical imaging
A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).

Y. Wen,M. Rodine,B. Arnold,H. McArthur,C. Barker,Zhigang Zhang,A. Gucalp,A. Phung,A. Ho,Lizza Lebron-Zapata

DOI: https://doi.org/10.1200/JCO.2018.36.5_SUPPL.14

2018-02-26

Abstract:14Background: Overall response rates of 13-19% have been reported with checkpoint inhibitor monotherapy in chemotherapy-resistant, PD-L1-positive mTNBC. RT is frequently used to enhance local control in mTNBC and has been reported to induce distant (abscopal) tumor responses when combined with immunotherapy. In this study, we evaluate the safety and efficacy of RT combined with a programmed cell death protein 1 (PD-1) inhibitor, pembro, in a single-arm, two-stage, phase II study in mTNBC. Methods: Eligible women had biopsy-proven mTNBC, ECOG performance status 0-2, and ≥2 measurable sites of metastatic disease with at least one site requiring RT. A total RT dose of 3000 cGy was delivered in 5 daily fractions. Pembro 200 mg was given intravenously within 3 days of first RT fraction, then every 3 weeks +/-3 days until disease progression. The primary endpoint was overall response rate at week 13 in the non-irradiated lesions by RECIST v1.1. Secondary endpoints included safety and overall survival. Tumor bio...

Medicine
Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.

Zin Myint,William H St. Clair,Stephen Strup,Patrick J. Hensley,Donglin Yan,Jonathan David Tward,Benjamin L. Maughan

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.tps351

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:TPS351 Background: Definitive radiation therapy (DRT) combined with androgen deprivation therapy (ADT) remains the standard of care in patients with high-risk prostate cancer (HRPC) who do not want surgery. However, up to 50% experience biochemical recurrence (BCR) within 5 years. A phase 3 NCIC group reported the 10-year biochemical recurrence free survival was 63% in ADT plus DRT vs. 27% in ADT alone. There is an urgent need for effective novel combination strategies. We hypothesize combined immune sensitizing effects of PARPi and radiation will result in significant activity of immunotherapy in men with HRPC. Methods: This is a multicenter phase II randomized study to assess biochemical response rates, safety and tolerability of combined therapy in pts with localized HRPC who elected for concurrent DRT. A total of 64 pts will be randomized 1:1 to receive either pembrolizumab (P) combined with olaparib or single agent P in addition to the standard of care ADT with DRT. Hypofractionated IMRT (2.4 to 4 Gy per fraction over 4-6 weeks) will be delivered and all pts will receive adjuvant P for one year and ADT for at least 18 months. All pts will undergo germline testing. Key eligible criteria include biopsy confirmed prostate adenocarcinoma who meets at least one of the four high-risk features: 1) clinical T3a, T3b or T4, 2) N1, 3) Gleason grade group 4 or 5, and 4) PSA >20 ng/ml. Patients with less than 2 cm pelvic nodes and received ADT therapy within 3months prior to study enrollment are allowed. PSA >150 ng/ml and patients with distant metastases will be excluded. The primary endpoint is to assess the proportion of patients who achieve a PSA nadir level of ≤ 0.06 ng/ml within six months after completion of radiation therapy in each arm. The secondary objectives include safety/tolerability, BCR and metastasis-free survival at 3 years. BCR is defined by the Phoenix definition. The study is designed to detect a 15% improvement in PSA nadir ≤ 0.06 ng/mL within 6 months after completion of the combined therapy versus historical control group data Geara FB et al., 2017. Enrollment began in August 2023. Clinical trial information: NCT05568550 .

oncology
Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani,Abraham Avigdor,Anna Maria Sureda Balari,David Lavie,Stefan Hohaus,Jan M. Zaucha,Vu Minh Hua,Vittorio Ruggero Zilioli,Raimundo Gazitua,Muhit Ozcan,Amos Odeleye-Ajakaye,Nishitha Reddy,Patricia Marinello,Jane N. Winter

DOI: https://doi.org/10.1182/blood-2023-181171

IF: 20.3

2023-11-28

Blood

Abstract:Introduction: The phase 2 KEYNOTE-C11 study (NCT05008224) evaluates the safety and efficacy of pembrolizumab (pembro) followed by AVD chemotherapy (chemotherapy) and pembro consolidation in patients with untreated, early unfavorable or advanced-stage cHL without radiotherapy. The criteria for study continuation were met at the pre-specified interim futility analysis after pembrolizumab induction and 2 cycles of AVD, with approximately 3 months of follow-up. We present results of an analysis of efficacy and safety in all enrolled patients with an additional 8 months of follow-up. Methods: Patients aged ≥18 years with newly-diagnosed, early unfavorable or advanced stage cHL, received induction with pembrolizumab 200 mg IV on d1 Q3W for 3 cycles, followed by a PET2 to determine response. All patients then received 2 cycles standard dose AVD on d1 and 15 for 2 cycles (chemotherapy phase 1) followed by PET3. Patients who were PET3-negative (Deauville score 1-3) received 2-4 additional cycles AVD based on bulk. Patients aged ≤60 years who were PET3-positive (Deauville score 4-5) received 2-4 cycles of escalated bleomycin plus etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escBEACOPP, chemotherapy phase 2). All patients then received consolidation pembrolizumab 400 mg Q6W for 4 cycles followed by a PET4 assessment. The primary endpoint for this analysis was investigator assessed PET3-negativity response in all treated patients. A posthoc PET analysis was also performed in the actuarial population of all treated patients who reached PET2 or PET3. Results: At data cut-off (Apr 5, 2023), the median (range) follow-up was 11.8 months (9.7-17.6). A total of 146 patients with untreated cHL were enrolled. Median (range) age was 34.5 years (18-78); 32 (22%) patients had bulky disease, 84 (57%) and 62 (43%), respectively, had advanced and early unfavorable disease. Of 146 patients, 137 (94%) had completed pembrolizumab monotherapy, 130 of 136 (96%) who proceeded to chemotherapy phase 1 completed chemotherapy phase 1, and 127 of 130 (98%) completed chemotherapy phase 2 (111 [AVD]; 16 [BEACOPP]). The PET2-negativity rate was 29% and 31% in all treated patients (N=146) and the actuarial population (n=137), respectively. The PET3-negativity rate was 70% and 78% in all treated patients (N=146) and the actuarial population (n=131), respectively. The ORR at end of PET2 and PET3 was 78% and 88%, respectively. Grade ≥3 drug related adverse events (AEs) were reported in 23 of 146 (16%) patients who received pembrolizumab alone or at consolidation, 94 of 136 (69%) patients who received AVD, and in 10 of 17 (59%) patients who received escBEACOPP. Immune mediated AEs were reported in 37 (25%) patients who received pembrolizumab alone and consolidation, most commonly hyperthyroidism (10%) and hypothyroidism (6%). There were no deaths due to study drug related or immune-mediated AEs. Conclusion: Pembrolizumab induction followed by chemotherapy continued to be well tolerated in patients with newly-diagnosed, early unfavorable, or advanced-stage cHL, with 70% achieving a PET3-negative response as assessed by investigator after the initial chemotherapy phase. There were no new safety concerns and study is ongoing.

hematology
Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer

Chaoyuan Liu,Liang Zeng,Chao Deng,Wenjuan Jiang,Yapeng Wang,Yiguang Zhou,Li Liu,Sisi Wang,Chunhua Zhou,Zhenhua Qiu,Fanxu Zeng,Fang Wu,Jie Weng,Xianling Liu,Nong Yang,Fang Ma

DOI: https://doi.org/10.3389/fimmu.2023.1175960

IF: 7.3

2023-06-07

Frontiers in Immunology

Abstract:Introduction: The combination of a PD-L1 inhibitor plus carboplatin/cisplatin and etoposide (EC/EP) has become a new standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Combining concurrent palliative hypofractionated radiotherapy of the thorax (HFRT) and immunochemotherapy may have a synergistic effect. In this study, we explored an optimal model of combination radiotherapy with immunochemotherapy as first-line treatment of ES-SCLC. Patients and methods: In this multicenter single-arm phase 2 trial, patients with ES-SCLC received atezolizumab with EC/EP for two cycles (induction phase), then, those who did not progress received concurrent palliative HFRT and two cycles of atezolizumab with EC/EP (combination phase). Afterward they received atezolizumab every 3 weeks for a maximum of 2 years after study enrolment (maintenance phase). Prophylactic cranial irradiation (PCI) was recommended. The primary endpoints were safety and tolerance; the second endpoints were progression-free survival (PFS). Results: Forty patients were enrolled, and all had completed palliative HFRT and four cycles of immunochemotherapy. There were seven grade 3 adverse events (3 decreased neutrophil count, 1 anemia, 2 pneumonitis, 1 esoenteritis), two grade 4 adverse events (2 decreased white cell count) and no grade 5 toxicities. The pneumonitis rate was 12.5% (three grade 2 and two grade 3 events). At the median follow-up of 14.2 months (range, 6.8–28.7), the median PFS was 8.6 months (95%CI, 6.1–11.1). Conclusion: The addition of concurrent hypofractionated thoracic radiotherapy to first-line immunochemotherapy for ES-SCLC was well tolerated and showed promising clinical efficacy. Additional randomized trials are needed to validate benefits. Clinical trial registration: https://clinicaltrials.gov/ (NCT 04636762).

immunology

[Epidemiologic study of sudden death in adults from 15 to 74 years of age in the city of São Paulo].

Data from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Neoadjuvant Hypofractionated Radiotherapy Combined with Pembrolizumab Plus Chemotherapy for Potentially Resectable Non-Small Cell Lung Cancer: A Phase Ib Study.

A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer

A Phase 2 Clinical Trial of Pembrolizumab with Radiation Following Progression on anti-PD-1 Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

[Results of tests with clomiphene and choriogonadotropin in men with oligozoospermia treated with longterm antiestrogens].

Delayed primary closure of Korean war wounds.

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC

Abstract CT120: Phase II study of radiotherapy in combination with chemotherapy and immunotherapy in patients with PD-L1-positive metastatic triple-negative breast cancer

Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA

Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes

Phase 2 Study of Pembrolizumab in Patients with Advanced Rare Cancers.

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Ku band second harmonic N-coupled push-push oscillator array using microstrip resonator

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker Correlatives

A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).

Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer